bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease
Retrieved on:
Thursday, September 29, 2022
Health, Neurology, Clinical Trials, Research, Science, Biotechnology, Motor neuron, TARDBP, Roivant Sciences, Central nervous system, IPSC, Culture, Memory, Neuron, FTD, Machine learning, University, Brain, AD, Disease, Microglia, CRISPR, Potency (pharmacology), Nobel Prize, Neurodegeneration, Series, Synthetic biology, Frontotemporal dementia, Language, Foresite Capital, Physiology, CEO, Technology, Biology, Atrophy, TAR, Cell, Frontotemporal lobar degeneration, Aggregation, Pathology, Founder, Drug development, Nobel Prize in Physiology or Medicine, Amyotrophic lateral sclerosis, Method, Research, ALS, Multimedia, Mutation, Drug discovery, HIV disease progression rates, Alzheimer's disease, Charles River Laboratories, Fine chemical, Vaccine, Pharmaceutical industry, Medical device, P2RY12, Tencent, Medicine
bit.bios latest cell products provide a scalable source of human cells and will enable scientists to study neurodegenerative diseases in a human context.
Key Points:
- bit.bios latest cell products provide a scalable source of human cells and will enable scientists to study neurodegenerative diseases in a human context.
- The launch of two new cell products for research and drug discovery in neurodegenerative diseases validates our cell identity coding platforms ability to create and manufacture any human cell type consistently at scale.
- Dr Farah Patell-Socha, VP Research Products at bit.bio, said:
Human cells are key to disease research, drug discovery, and clinical translation. - These disease models offer a fast and easy-to-use system for investigations into the impact of gene function on disease progression.